Microscopic polyangiitis
Microscopic polyangiitis (MPA) is a systemic necrotizing vasculitis that mainly affects small blood vessels. It can invade small arteries, arterioles, capillaries, and venules in organs such as the kidneys, skin, and lungs. It often manifests as necrotizing glomerulonephritis and pulmonary capillaritis. In 1948, Davson et al. first proposed that there was a subtype of polyarteritis nodosa characterized by segmental necrotizing glomerulonephritis, which was called microscopic polyarteritis. Because it mainly affects small blood vessels including veins, it is now often called microscopic polyangiitis. The 1990 American College of Rheumatology classification criteria for vasculitis did not list MPA separately, so most microscopic polyangiitis in the past was classified as polyarteritis nodosa (PAN), and very few were classified as Wegeners granulomatosis (WG). It is generally believed that microscopic polyangiitis is an independent systemic necrotizing vasculitis with little or no immune complex deposition, and necrotizing glomerulonephritis and pulmonary capillaritis are common. The 1993 Chapel Hill Conference defined microscopic polyangiitis as a necrotizing vasculitis that mainly affects small blood vessels (such as capillaries, venules or arterioles) without immune complex deposition. The difference between PAN and MPA is that the former lacks vasculitis of small blood vessels, including arterioles, capillaries and venules. Given that MPA, WG and CSS (Churg-Strauss syndrome) have similar characteristics of ANCA positivity and lack of immune complex deposition, they are often collectively referred to as ANCA-associated vasculitis.
-
Site of disease:
Blood vessels kidney lungs -
Infectious :
Not contagious -
Frequent population:
All groups -
Related symptoms:
Fever Anorexia Fatigue Joint pain Weight loss -
Concurrent disease:
Related Drugs
Blood and urine capsules
Manufacturer:
Zhengzhou Xiehe Pharmaceutical Factory
RUXIENCE- rituximab-pvvr_injection, solution
Indication: RUXIENCE is a CD20-directed cytolytic antibody indicated for the treatment of: 1. 1 o o o o 1. 2 o 1. 4 RUXIENCE is indicated for the treatment of adult patients with: RUXIENCE, in combination with fludarabine and cyclophosphamide (FC), is indicated for the treatment of adult patients with previously untreated and previously treated CD20-positive CLL. RUXIENCE, in combination with methotrexate, is indicated for the treatment of adult patients with moderately-to severely-active rheumatoid arthritis who have had an inadequate response to one or more Tumor Necrosis Factor (TNF) antagonist therapies. RUXIENCE, in combination with glucocorticoids, is indicated for the treatment of adult patients with Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA).
Manufacturer:
Pfizer Laboratories Div Pfizer Inc
RIABNI- rituximab-arrx_injection, solution
Indication: RIABNI is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1. 1 Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or other anthracycline-based chemotherapy regimens. Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1. 2 Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately- to-severely- active RA who have inadequate response to one or more TNF antagonist therapies ( 1. 3 Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult patients in combination with glucocorticoids ( 1. 4 Moderate to severe Pemphigus Vulgaris (PV) in adult patients ( 1. 5 RIABNI is indicated for the treatment of adult patients with: Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens. RIABNI, in combination with fludarabine and cyclophosphamide (FC), is indicated for the treatment of adult patients with previously untreated and previously treated CD20-positive CLL. RIABNI, in combination with methotrexate, is indicated for the treatment of adult patients with moderately- to-severely- active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies. RIABNI, in combination with glucocorticoids, is indicated for the treatment of adult patients with Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA). RIABNI is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.
Manufacturer:
Amgen Inc
RIABNI- rituximab-arrx_injection, solution
Indication: RIABNI is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1. 1 Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or other anthracycline-based chemotherapy regimens. Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1. 2 Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately- to-severely- active RA who have inadequate response to one or more TNF antagonist therapies ( 1. 3 Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult patients in combination with glucocorticoids ( 1. 4 Moderate to severe Pemphigus Vulgaris (PV) in adult patients ( 1. 5 RIABNI is indicated for the treatment of adult patients with: Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens. RIABNI, in combination with fludarabine and cyclophosphamide (FC), is indicated for the treatment of adult patients with previously untreated and previously treated CD20-positive CLL. RIABNI, in combination with methotrexate, is indicated for the treatment of adult patients with moderately- to-severely- active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies. RIABNI, in combination with glucocorticoids, is indicated for the treatment of adult patients with Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA). RIABNI is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.
Manufacturer:
Amgen, Inc
Related Ingredients
-
SMILAGENIN list
126-18-1